Michael Dybbs

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.

The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA.

New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group.

Advanced Cell Diagnostics, Inc. operates as a biotechnology company. It specializes in the emerging field of molecular pathology and developing cell- and tissue-based diagnostic tests for personalized medicine. The company was founded by Lou Yuling and Steve Chan in 2006 and is headquartered in Newark, CA.

Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA.

Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA.